TUMOUR-INFORMED CTDNA

 

Detect what your current platform misses.


Ultra-sensitive ctDNA monitoring for your clinical trial, your laboratory, your patients. Delivered as a service from our EU lab, or run on your own instruments.

✓ Parts-per-million sensitivity · Open pipeline, raw data access · EU-based

simsen-lab-02-blue-overlay
WHERE TO START

 

Three audiences. Three places to begin.

Whoever you are, start with the outcome you need. The science is one click deeper, for when you want it.

———

For clinical trials

Validate MRD endpoints. Move faster.

Design ctDNA endpoints into your European oncology trial, with raw data access and co-publication built in.

Design a trial assay →

———

For research and laboratories

See signals others miss.

Send samples, or bring SiMSen-Seq in-house on your own instruments. Low-AF detection in paediatric and early-stage samples.

Explore both options →

———

For clinics

Catch relapse before imaging does.

Personalised ctDNA monitoring for your oncology patients, with EU logistics and time-zone-aligned support.

Order an assay →
WHY SIMSEN

 

Ultra-sensitive ctDNA, delivered your way.

Five reasons researchers, pharma teams and clinics across Europe choose to work with us.

01

Sensitivity

You detect signal at parts-per-million, in samples your current platform may call negative.

02

Flexibility

You choose: send samples to our accredited lab, or run SiMSen-Seq on your own instruments.

03

Clinical insight

You see actionable variants and tumour evolution, not just a binary positive or negative.

04

Transparency

You get full raw data access and an open analysis pipeline. Your bioinformatics team can verify, reanalyse or extend our results with their own tools.

05

Partnership

You work with a specialist team: co-publication, protocol design and interpretation help.

TRUSTED BY LEADING EUROPEAN CLINICS, HOSPITALS AND BIOTECHS

Docrates
VHiO
Sahlgrenska-1
OneCarbon
EpistaMaiBio
Neogap
EVIDENCE

 

What ultra-sensitivity looks like for the people doing the work.

 

<0.001%

 

9 months

 

3-5 ppm
Variant allele frequency you can detect, in your own samples. Earlier than imaging picked up relapse, in paediatric sarcoma monitoring.
 Residual ctDNA you can see three days after pancreatic surgery.
SIMSEN-SEQ, NATURE PROTOCOLS → EK ET AL., 2024 → PRELIMINARY, STUDY ONGOING →

 

METHODOLOGY

 

Three ways to monitor ctDNA. They are not interchangeable.

Tumour-informed monitoring splits broadly into three approaches: tracking single nucleotide variants, tracking structural variants, or using fixed tumour-naive panels. Each has consequences for your samples. Most platforms hide this choice. We think it deserves daylight.

———
SNV-based

 SIMSEN APPROACH

Personalised and ultra-sensitive, surfacing clinically actionable variants alongside tumour markers.

Best when: small biopsies, low tumour burden, you want resistance signal.

 

———
SV-based

  

Personalised, sensitive in tumour types with high structural-variant burden, but no resistance information.

Best when: SV-rich tumours, resistance tracking not required.

 

———
Tumour-naive

  

Fixed panel, no biopsy needed, lower sensitivity at very low allele frequencies.

Best when: No tissue available, sensitivity is secondary.

 
Read the full methodology framework →